Cargando…

The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease

BACKGROUND: Simple and effective risk models incorporating biomarkers associated with left main coronary artery (LMCA) stenosis are limited. This study aimed to validate the novel Bio-Clinical SYNTAX score (Bio-CSS) incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jae Yong, Lee, Jang Hoon, Kim, Hong Nyun, Kim, Namkyun, Jang, Se Yong, Bae, Myung Hwan, Yang, Dong Heon, Park, Hun Sik, Cho, Yongkeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538309/
https://www.ncbi.nlm.nih.gov/pubmed/36211557
http://dx.doi.org/10.3389/fcvm.2022.912286
_version_ 1784803335816085504
author Yoon, Jae Yong
Lee, Jang Hoon
Kim, Hong Nyun
Kim, Namkyun
Jang, Se Yong
Bae, Myung Hwan
Yang, Dong Heon
Park, Hun Sik
Cho, Yongkeun
author_facet Yoon, Jae Yong
Lee, Jang Hoon
Kim, Hong Nyun
Kim, Namkyun
Jang, Se Yong
Bae, Myung Hwan
Yang, Dong Heon
Park, Hun Sik
Cho, Yongkeun
author_sort Yoon, Jae Yong
collection PubMed
description BACKGROUND: Simple and effective risk models incorporating biomarkers associated with left main coronary artery (LMCA) stenosis are limited. This study aimed to validate the novel Bio-Clinical SYNTAX score (Bio-CSS) incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with LMCA stenosis. METHODS: Patients who underwent percutaneous coronary intervention (PCI) for LMCA stenosis using a drug-eluting stent (n = 275) were included in the study. We developed the Bio-CSS incorporating NT-proBNP and validated the ability of the Bio-CSS to predict major adverse cardiac events (MACEs) and compared its performance to that of the SYNTAX score (SS) and SS II. The MACEs were defined as death, non-fatal myocardial infarction (MI), and repeat revascularizations. RESULTS: The Bio-CSS (34.7 ± 18.3 vs. 51.9 ± 28.4, p < 0.001), as well as SS (23.6 ± 7.3 vs. 26.7 ± 8.1, p = 0.003) and SS II (29.4 ± 9.9 vs. 36.1 ± 12.8, p < 0.001), was significantly higher in patients with MACEs. In the Cox proportional hazards model, the log Bio-CSS (hazard ratio 8.31, 95% CI 1.84–37.55) was an independent prognostic factor for MACEs after adjusting for confounding variables. In the receiver operating characteristic curves, the area under the curve of the Bio-CSS was significantly higher compared to those of SS (0.608 vs. 0.706, p = 0.001) and SS II (0.655 vs. 0.706, p = 0.026). Patients were categorized into the three groups based on the tertiles of the Bio-CSS. Patients in the highest tertile of the Bio-CSS had significantly higher MACEs compared to those in the lower two tertiles (log-rank p < 0.001). CONCLUSION: In patients who underwent PCI for LMCA stenosis, the novel Bio-CSS improved the discrimination accuracy of established combined scores, such as SS and SS II. The addition of NT-proBNP to the clinical and angiographic findings in the Bio-CSS could potentially provide useful long-term prognostic information in these patients.
format Online
Article
Text
id pubmed-9538309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95383092022-10-08 The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease Yoon, Jae Yong Lee, Jang Hoon Kim, Hong Nyun Kim, Namkyun Jang, Se Yong Bae, Myung Hwan Yang, Dong Heon Park, Hun Sik Cho, Yongkeun Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Simple and effective risk models incorporating biomarkers associated with left main coronary artery (LMCA) stenosis are limited. This study aimed to validate the novel Bio-Clinical SYNTAX score (Bio-CSS) incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with LMCA stenosis. METHODS: Patients who underwent percutaneous coronary intervention (PCI) for LMCA stenosis using a drug-eluting stent (n = 275) were included in the study. We developed the Bio-CSS incorporating NT-proBNP and validated the ability of the Bio-CSS to predict major adverse cardiac events (MACEs) and compared its performance to that of the SYNTAX score (SS) and SS II. The MACEs were defined as death, non-fatal myocardial infarction (MI), and repeat revascularizations. RESULTS: The Bio-CSS (34.7 ± 18.3 vs. 51.9 ± 28.4, p < 0.001), as well as SS (23.6 ± 7.3 vs. 26.7 ± 8.1, p = 0.003) and SS II (29.4 ± 9.9 vs. 36.1 ± 12.8, p < 0.001), was significantly higher in patients with MACEs. In the Cox proportional hazards model, the log Bio-CSS (hazard ratio 8.31, 95% CI 1.84–37.55) was an independent prognostic factor for MACEs after adjusting for confounding variables. In the receiver operating characteristic curves, the area under the curve of the Bio-CSS was significantly higher compared to those of SS (0.608 vs. 0.706, p = 0.001) and SS II (0.655 vs. 0.706, p = 0.026). Patients were categorized into the three groups based on the tertiles of the Bio-CSS. Patients in the highest tertile of the Bio-CSS had significantly higher MACEs compared to those in the lower two tertiles (log-rank p < 0.001). CONCLUSION: In patients who underwent PCI for LMCA stenosis, the novel Bio-CSS improved the discrimination accuracy of established combined scores, such as SS and SS II. The addition of NT-proBNP to the clinical and angiographic findings in the Bio-CSS could potentially provide useful long-term prognostic information in these patients. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9538309/ /pubmed/36211557 http://dx.doi.org/10.3389/fcvm.2022.912286 Text en Copyright © 2022 Yoon, Lee, Kim, Kim, Jang, Bae, Yang, Park and Cho. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Yoon, Jae Yong
Lee, Jang Hoon
Kim, Hong Nyun
Kim, Namkyun
Jang, Se Yong
Bae, Myung Hwan
Yang, Dong Heon
Park, Hun Sik
Cho, Yongkeun
The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title_full The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title_fullStr The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title_full_unstemmed The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title_short The novel bio-SYNTAX scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
title_sort novel bio-syntax scoring system for predicting the prognosis of patients undergoing percutaneous coronary intervention with left main coronary artery disease
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538309/
https://www.ncbi.nlm.nih.gov/pubmed/36211557
http://dx.doi.org/10.3389/fcvm.2022.912286
work_keys_str_mv AT yoonjaeyong thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT leejanghoon thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT kimhongnyun thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT kimnamkyun thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT jangseyong thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT baemyunghwan thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT yangdongheon thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT parkhunsik thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT choyongkeun thenovelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT yoonjaeyong novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT leejanghoon novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT kimhongnyun novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT kimnamkyun novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT jangseyong novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT baemyunghwan novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT yangdongheon novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT parkhunsik novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease
AT choyongkeun novelbiosyntaxscoringsystemforpredictingtheprognosisofpatientsundergoingpercutaneouscoronaryinterventionwithleftmaincoronaryarterydisease